Stalicla is a precision neuro clinical stage company. Funded in 2017, Stalicla has raised over $80m in private capital and non dilutive funding. Stalicla’s shareholders include Novartis, Pitcted, Edmmond de Rothschild and SPRIM. Stalicla has successfully developed a unique neuro platform, DEPI, with a first application in precsion Autism Sepctrum Disorder through the clinical development of 2 precision autism assets: STP1 and STP2 entering Phase 2. Stalicla has also developed a mGluR5 NAM platform with its lead asset, STP7 (mavoglurant) licensed from Novartis, entering Phase III in partnership with the National Insitute of Health. Stalicla mGluR5 platform offers multi-faceted late-stage clinical development opportunities in the field of CNS. STALICLA is now preparing a 65m-Series C to support STP1 & STP2 phase 2, develop STP7 around substance use disorders and additional CNS indications and expend its neuro precision pipeline through the in licensing and development of a new PhII asset for which Stalicla has already secured a $24m of credit line.